by Dennis Crouch Novartis v. Torrent Pharma, Apotex, and Mylan (Fed. Cir. 2017) At the conclusion of its Inter Partes Review (IPR) Trial, the Patent Trial & Appeal Board (PTAB) found all claims of Novartis U.S. Patent No. 8,324,283 invalid as obvious.  The PTAB had allowed Novartis to include substitute claims as well, but found those also … Continue reading Generics Successful at Invalidating Novartis Gilenya Patent